ORIC Pharmaceuticals Q3 2024 Earnings Report

ORIC Pharmaceuticals reported financial results for the third quarter of 2024 and provided operational updates.

Key Takeaways

ORIC Pharmaceuticals reported cash and investments of $282.4 million, expected to fund the operating plan into late 2026. The company continues to advance ORIC-114 and ORIC-944 programs towards registrational studies. Clinical collaborations were announced to support the ORIC-944 trial in combination with AR inhibitors for prostate cancer.

Presented preclinical data supporting ORIC-114's potential as a best-in-class treatment for EGFR exon 20 insertions and other atypical mutations.

Announced clinical collaborations to support the trial evaluating ORIC-944 in combination with AR inhibitors for prostate cancer.

Cash and investments of $282.4 million are expected to fund the operating plan into late 2026.

Initiated dosing of ORIC-944 in combination with NUBEQA® (darolutamide) and in combination with ERLEADA® (apalutamide) in the ongoing Phase 1b trial for prostate cancer in first half of 2024.

Previous year: -$0.44

+11.4%

Gross Profit

-$270K

Previous year: -$257K

+5.1%

Cash and Equivalents